ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in New York, NY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Multiple Sclerosis
Sclerosis
Chronic Progressive Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Autoimmune Diseases
Neoplasm Metastasis
Cognitive Dysfunction

Multiple Sclerosis (MS) trials near New York, NY, USA:

Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) (BEAT-MS)

of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized...

Enrolling
Secondary Progressive Multiple Sclerosis
Relapsing Multiple Sclerosis
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Biological: Best Available Therapy (BAT)

Phase 3

National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)

New York, New York, United States and 19 other locations

A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants with multiple...

Active, not recruiting
Multiple Sclerosis (MS)
Drug: Ocrelizumab
Drug: rHuPH20

Phase 1

Roche
Roche

New York, New York, United States and 20 other locations

A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) (FUSION)

In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is...

Enrolling
Relapsing Forms of Multiple Sclerosis
Drug: BIIB091
Drug: DRF

Phase 2

Biogen
Biogen

Teaneck, New Jersey, United States and 76 other locations

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS...

Enrolling
Multiple Sclerosis
Drug: Interferon beta-1a
Drug: Placebo capsule

Phase 3

Novartis
Novartis

New Brunswick, New Jersey, United States and 107 other locations

A Clinical Study to Evaluate the Potential Role of ACTH Gel in Patients With Scleritis (ATLAS)

(maintenance) in people with systemic lupus erythematosus (lupus), infantile spasms, adults with acute relapses or flares of multiple sclerosis...

Enrolling
Scleritis
Drug: ACTH (adrenocorticotropic hormone) gel

Phase 2

Metropolitan Eye Research & Surgery Institute

Palisades Park, New Jersey, United States of America and 2 other locations

Locations recently updated

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis...

Enrolling
Relapsing Multiple Sclerosis
Drug: Placebo
Drug: Obexelimab

Phase 2

Zenas BioPharma

Teaneck, New Jersey, United States of America and 27 other locations

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation (SOSTOS)

This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofat...

Enrolling
Relapsing-Remitting Multiple Sclerosis
Drug: Disease modifying treatment (DMT)
Drug: Ofatumumab

Phase 4

Novartis
Novartis

Neptune, New Jersey, United States and 36 other locations

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS) (Operetta 2)

This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with...

Active, not recruiting
Relapsing-Remitting Multiple Sclerosis
Drug: Ocrelizumab
Drug: Fingolimod

Phase 3

Roche
Roche

New Brunswick, New Jersey, United States and 111 other locations

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab (ARTIOS)

Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or...

Active, not recruiting
Relapsing Multiple Sclerosis
Biological: Ofatumumab

Phase 3

Novartis
Novartis

Woodmere, New York, United States and 122 other locations

Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls. (AGNOS)

This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early...

Active, not recruiting
Relapse Remitting Multiple Sclerosis
Drug: Ofatumumab

Phase 4

Novartis
Novartis

Hackensack, New Jersey, United States and 35 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems